Our science is geared towards care of human lives
Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. Our technology is based on the extraction of bacterial strains from unexplored soil environments and the identification of bacteriophages, -lytic and lysogenic-, that prevail in those exotic bacterial populations.
This is the basis to develop unique phage libraries, providing us new avenues for the discovery and development of potent antibacterial agents using lytic phage enzymes as a new innovative tool to treat human infections diseases. Bacteriophage lysins have long been demonstrated to be effective enzybiotics in various infectious models.
Thanks to its modular structure, with at least two distinct domains (enzymatic hydrolysis and substrate recognition), we can combine the different modules and produce, through synthetic biology, new enzybiotics with desired properties, such as higher activity or a broader spectrum of destruction. Moreover, lysins can even be engineered to kill bacterial pathogens from without, a property that is not present in natural lysins.
Two types of lytic enzymes
Telum develops two main kinds of lytic enzymes: natural lytic enzymes (NLEs) and chimeric lytic enzymes (CLEs).
NLEs are obtained, directly, from bacteriophage sequence. They are referred to as ‘endolysins’ and designed by the majority of bacteriophages to enzymatically degrade the peptidoglycan (PG) layer of the host bacterium `from within’ at the end of their lytic multiplication cycle.
CLEs may be defined as synthetic biological products obtained as a result of combination of different modules, binding and catalytic domain, taken from different lytic enzymes family.
By connecting chemistry and physics of this proteins, Telum is leveraging the combinative potential of these two approaches to advance new research.